Skip to main content
SpringerLink
Log in

Quantitation of hepatic and pulmonary first-pass effect and its implications in pharmacokinetic study. I. Pharmacokinetics of chloroform in man

  • Published:
Journal of Pharmacokinetics and Biopharmaceutics Aims and scope Submit manuscript

Abstract

Theoretical equations are derived to estimate the extent of the hepatic and pulmonary first-pass effect after oral and intraperitoneal administration. This first-pass effect is taken into consideration for the determination of apparent volume of distribution and body clearance. Calculations using data for two normal adult subjects taken from the literature suggest that the fractions of chloroform metabolized in the liver and excreted intact from the lung in the first pass are maximally 0.38 and 0.172. respectively. The apparent volumes of distribution of chloroform in these two subjects are 238 and 283% of their body weight in terms of blood concentration. Close agreement between the predicted and experimental values for the pulmonary excretion clearance is also found.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. P. A. Harris and S. Riegelman. Influence of route of administration on the area under the plasma concentration-time curve.J. Pharm. Sci. 58: 71–75 (1969).

    Article  CAS  PubMed  Google Scholar 

  2. M. Gibaldi and S. Feldman. Pharmacokinetic basis for the influence of route of administration on the area under the plasma concentration-time curve.J. Pharm. Sci. 58: 1477–1480 (1969).

    Article  CAS  PubMed  Google Scholar 

  3. M. Gibaldi, R. N. Boyes, and S. Feldman. Influence of first-pass effect on availability of drug on oral administration.J. Pharm. Sci. 60: 1338–1340 (1971).

    Article  CAS  PubMed  Google Scholar 

  4. D. Perrier and M. Gibaldi. Influence of first-pass effect on the systemic availability of propoxyphene.J. Clin. Pharmacol. 12: 449–452 (1972).

    CAS  Google Scholar 

  5. M. Rowland. Influence of route of administration on drug availability.J. Pharm. Sci. 61: 70–74 (1972).

    Article  CAS  PubMed  Google Scholar 

  6. M. Gibaldi and S. Feldman. Route of administration and drug metabolism.Eur. J. Pharmacol. 19: 323–329 (1972).

    Article  CAS  PubMed  Google Scholar 

  7. G. H. Evans and D. G. Shand. Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man.Clin. Pharmacol. Ther. 14: 487–493 (1973).

    CAS  PubMed  Google Scholar 

  8. M. Rowland. Effect of some physiologic factors on bioavailability of oral dosage forms. In Swarbrick, J. (ed.),Current Concepts in Pharmaceutical Sciences: Dosage Form Design and Bioavailability, Lea and Febiger, Philadelphia.

  9. S. Riegelman and M. Rowland. Effect of route of administration on drug disposition.J. Pharmacokin. Biopharm. 1: 419–434 (1973).

    Article  CAS  Google Scholar 

  10. E. J. Pantuck, K. C. Hsiao, A. Maggio, K. Nakamura, R. Kuntzman, and A. H. Conney. Effect of cigarette smoking on phenacetin metabolism.Clin. Pharmacol. Ther. 15: 9–17 (1974)

    CAS  PubMed  Google Scholar 

  11. P. J. Pentikainen, S. H. Wan, and D. L. Azarnoff. Bioavailability of aminosalicylic acid and its various salts in humans. IV. Comparison of four brands of the sodium salt.J. Pharm. Sci. 63: 1431–1434 (1974).

    Article  CAS  PubMed  Google Scholar 

  12. W. L. Chiou. Dose- and dosage form-dependent pharmacokinetics of phenacetin and its metabolite in man.J. Clin. Pharmacol. 14: 418–425 (1974).

    Article  CAS  PubMed  Google Scholar 

  13. W. L. Chiou. Apparent volume of distribution, pulmonary clearance and bioavailability of volatile or gaseous compounds after peripheral intravenous dosing.Res. Commun. Chem. Pathol. Pharmacol. 7: 679–686 (1974).

    CAS  PubMed  Google Scholar 

  14. S. Niazi and W. L. Chiou. Fluorocarbon aerosol propellants. IV. Pharmacokinetics of trichloromonofluoromethane following single and multiple dosing in dogs.J. Pharm. Sci. 64: 763–769 (1975).

    Article  CAS  PubMed  Google Scholar 

  15. A. Grollman and E. F. Grollman.Pharmacology and Therapeutics, Lea and Febiger, Philadelphia, 1970, pp. 80–81.

    Google Scholar 

  16. J. B. Terrill. Arterial venous blood levels of chloropentafluoroethane: Inhalation versus oral exposures.Am. Ind. Hyg. Assoc. J. 35: 269–275 (1974).

    Article  CAS  PubMed  Google Scholar 

  17. B. J. Fry, T. Taylor, and D. E. Hathway. Pulmonary elimination of chloroform and its metabolite in man.Arch. Int. Pharmacodyn. 196: 98–111 (1972).

    CAS  PubMed  Google Scholar 

  18. A. C. Guyton.Textbook of Medical Physiology, 4th ed., Saunders, Philadelphia, 1971, pp. 311 and 369.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, College of Pharmacy, and Occupational and Environmental Medicine, School of Public Health, University of Illinois Medical Center, 60612, Chicago, Illinois

    Win L. Chiou

Authors
  1. Win L. Chiou
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chiou, W.L. Quantitation of hepatic and pulmonary first-pass effect and its implications in pharmacokinetic study. I. Pharmacokinetics of chloroform in man. Journal of Pharmacokinetics and Biopharmaceutics 3, 193–201 (1975). https://doi.org/10.1007/BF01067908

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01067908

Key words

Search

Navigation